Hematopoietic Stem Cell Transplantation Archives

Risk-stratification technology is evolving in chronic lymphocytic leukemia and can be used to guide treatment decisions and direct patients to clinical trials.

CAR T Cell Therapy May Not Improve Survival vs Chemotherapy in B-ALL After Allo-HSCT

By

July 1, 2021

Researchers sought to determine whether CAR T therapy would have a better result than pretransplant chemotherapy in patients with B-ALL undergoing allo-HSCT.

Over half of evaluable patients who received an infusion of tisagenlecleucel achieved response.

Lymphoma

Survival Rates for Allogeneic, Autologous HSCT Are Similar in Patients With R/R Peripheral T-Cell Lymphoma

By

Jessica Nye, PhD

June 22, 2021

Researchers sought to determine which hematopoietic stem cell transplantation procedure is more efficacious for patients with refractory/relapsed peripheral T-cell lymphoma.

Lymphoma

Chemotherapy Followed by Autologous Stem Cell Transplantation Shows Promise as First-Line Treatment for T-Cell Non-Hodgkin Lymphoma

By

Patricia Chaney

June 17, 2021

Researchers sought to determine whether first-line chemotherapy followed by high-dose therapy and auto-SCT would be the preferred treatment for patients under 60 with T-NHL.

Mortality and relapse incidence were assessed in patients with NHL.

Leukemia

Leukemia-Specific T-cells Promising for Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

By

Patricia Chaney

June 14, 2021

Researchers sought to determine whether leukemia-specific T-cells would be a safe treatment for patients with AML or MDS after HSCT.

As follicular lymphoma (FL) survival rates have improved, concern that patients are at increased risk for the development of a secondary primary malignancy (SPM) has arisen.

General Hematology

Anti-T Cell Lymphocyte Globulin Shows Similar Long-Term Outcomes to Post-Transplant Cyclophosphamide for GVHD Prophylaxis

By

Jonathan Goodman, MPhil

June 3, 2021

Researchers sought to determine if GVHD prophylaxis with ATLG would be the same as PTCy in terms of long-term outcomes.

Infections often precede a formal diagnosis of CLL. Researchers found that antimicrobial use began to rise 6 years prior to CLL diagnosis.

General Hematology

BAFF May Be Promising Therapeutic Target in Graft-Vs-Host Disease

By

Jonathan Goodman, MPhil

June 2, 2021

Researchers sought to determine whether targeting BAFF and BCR pathways may improve outcomes in patients with chronic GVHD risk.

There are currently limited data on recipients of allogeneic HCT from alternative graft sources.

General Hematology

Knowledge of Human Leukocyte Antigen Loss After Haploidentical Transplantation Helps Manage Patients With Hematologic Malignancies

By

Vicki Moore, PhD

May 26, 2021

Researchers sought to determine whether detecting HLA loss would be helpful in managing patients with hematologic malignancies who relapsed after haploidentical transplantation.

A clinician prepares for hematopoietic stem cell transplantation.

General Hematology

Risk Factors for Graft Rejection and Pediatric Hematopoietic Stem Cell Transplantation

By

Vicki Moore, PhD

May 17, 2021

Researchers sought to determine risk factors for graft rejection in pediatric patients receiving hematopoietic stem cell transplantation for bone marrow failure.

General Hematology

Factors Associated With Mortality Following COVID-19 in Recipients of Hematopoietic Cell Transplant

By

Lauren Dembeck, PhD

May 3, 2021

Researchers have identified various factors associated with mortality following a diagnosis with the COVID-19 virus among recipients of allogeneic and autologous HCT.

Lymphoma

Engineered Cell Therapy AB-205 Shows Efficacy in Lymphoma With HDT-AHCT

By

Ariela Katz

April 26, 2021

Researchers sought to determine whether AB-205 would be a safe and effective therapy added to HDT-AHCT in adult patients with lymphoma.